Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15364 participants.
Also called NCT07626411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 15,364 participants
- Sponsor
- Registry
-
NCT07626411 -
2025-521617-97-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Japan
- Registry status
- Recruiting
Technical summary
Registry record NCT07626411. Randomized; quadruple masking; primary purpose prevention. Start 2026-08-10 (actual); primary completion 2029-09-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- Acronym
- ROXI-EVEREST
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07626411- Content hash
29eb452677ab9ca6b1894a9c3201cd346c08bf605fbd86f48a3ddd1280af951c